Oncogenic mutations of RAS, particularly KRAS, are found in a significant proportion of human cancers, including gastrointestinal (< 50%), pancreatic (13.37%), and lung (12.75%) cancers (Fig. 1) [1]. This evidence concerns the gene KRAS and cancer.